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A B S T R A C T
The upsurge of novel nanomaterials and nanotechnologies has inspired the researchers who
are striving for designing safer and more efficient drug delivery systems for cancer therapy.
Stimuli responsive nanomaterial offered an alternative to design controllable drug deliv-
ery system on account of its spatiotemporally controllable properties. Additionally, external
stimuli (light, magnetic field and ultrasound) could develop into theranostic applications
for personalized medicine use because of their unique characteristics. In this review, we
give a brief overview about the significant progresses and challenges of certain external-
stimuli responsive systems that have been extensively investigated in drug delivery and
theranostics within the last few years.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Based on advances in nanotechnologies and insight into the
pathology of cancer at the cellular and molecular levels, a large
sum of well-tailored nanoscale carrier platforms have been de-
veloped such as liposome, dendrimer, polymer nanoparticle and
inorganic nanoparticles made of iron oxide, quantum dots, gold
or other metal frameworks. (Fig. 1)
Nanotechnologies hold numerous advantages in drug de-
livery field including their ability to incorporate payloads with
different solubility into carriers [1], improve the in vivo phar-
macokinetic (PK) process of drugs [2], enhance their stability
and longevity in the blood circulation with or without addi-
tional structure modifications [3] and modify the carriers with
targeting ligands on their surface for tissue or cell-specific de-
livery to minimize side-effects [4]. Amongmyriads of successful
applications, stimuli-responsive “smart” nanocarriers have
emerged as a promising nanotechnology in comparison with
conventional nanoscale materials as a result of their unique
stimuli-responsive nature. In addition, compared with various
internal cues in the microenvironment of cancer, triggers from
outside offered better spatially and temporally controllable fea-
tures for activation and release of the loaded cargoes.
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This review aims to discuss such novel nanomaterials that
can be responsive to external stimuli, which have been ex-
ploited for cancer therapy and simultaneously can be used for
diagnosis. In the interest of brevity, this review does not elabo-
rate equally important internal stimuli and other fields that
have not been widely studied yet, thus, the external stimuli
we single out are light, magnetic field and ultrasound. Not only
can they be used for fabricating stimuli-responsive systems but
can potentially integrate therapy and imaging into single plat-
form for theranostic applications which indicate a promising
future in the forthcoming personalized medicine.
2. General concepts of stimuli-responsive
system
The working mechanisms of stimuli-responsive systems are
always alike: after injecting intravenously (or other adminis-
tration mode like intraperitoneal injection), nanocarriers would
leak through neovascular and accumulate at the tumor lesion
via passive targeting (enhanced permeability and retention
effect) or active targeting (i.e. based on the receptor-ligand af-
finity principle, exploiting folic acid-modified nanocarriers to
actively bind to folic acid receptor over-expressed tumor cells
so that could improve nanocarriers accumulation in tumor site),
then, delivery systems can be activated by single or several spe-
cific triggers from inner or outer body and release the bioactive
cargoes in the intended sites.
Specific triggers could be roughly divided into two catego-
ries: The first part is termed “intrinsic-stimuli” since they are
local stimuli within the tumor microenvironment. As sophis-
ticated as tumor, themicroenvironment of pathological site have
certain peculiar attributes compared with healthy one and these
peculiarities could be used to design internal-stimuli sensi-
tive delivery system. For example, pH-sensitive nanocarries have
been applied continually to construct responsive systems for
drug delivery since they can stabilize the integral particle at
physiological pH during circulation in vasculature but release
payloads while the system reaching tumor site and triggered
by the lower pH value of the tumor microenvironment [5].Thus
the payloads just release specifically within the tumor site and
reduce the unwanted side effect [6]. Other intrinsic stimuli such
as temperature, redox, and enzyme activity have been ex-
ploited extensively in biomedical research as well.
There are a number of other parameters beyond the inner
body which are termed as “external stimuli” including mag-
netic fields, ultrasound, light, etc. Compared with the “internal-
stimuli” that make use of characteristics within tumor
microenvironment like lower pH value, higher temperature as
mentioned above, the external stimuli responsive systems could
intrinsically or introduce contrast agents to visualize the ac-
cumulation of nanoparticles in the target tissues, cells or
organelles and then activate the nanocarriers out of body by
light or other triggers at desired time. Therefore, the con-
trolled release is more spatiotemporal and has higher potential
for clinical applications.
All in all, the primary principles of responsive delivery
system could be described as follow: upon exposing to spe-
cific stimuli from the interior or exterior, their chemical
composition or physical structure would undergo a given trans-
formation that induces the release of payloads or activation
of prodrugs and reacting in a controllable way.
3. Light responsive systems
Since 1994 the first photosensitizer has been approved by the
U.S. Food and Drug Administration (FDA), and the advent of
photo-responsive therapy has made an inspiring impact on the
field of cancer therapy owing to its non-invasiveness and spa-
tiotemporally controllable ability.
Once exposed to irradiation in specific wavelength range
directly, photosensitizer molecules would absorb the energy
from light and turn into highly unstable state, then transfer
energy to surrounding oxygen molecules, generate reactive
oxygen species (ROS) to damage nearby biomolecules, or convert
absorbed energy into heat, raising local temperature [7] or the
energy would be released by emitting photons that possess
Fig. 1 – Schematic illustrations summarized various external stimuli employed for responsive nanosystems following
systemic administration of different nanopreparations.
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lower power and eventually, the activated molecules turn back
to ground state.
Hence, in the light of the different function mechanisms
of photosensitive materials, light-triggered treatment could be
divided into three different types including photodynamic
therapy (PDT), photothermal therapy (PTT), and light-triggered
cargo release.
3.1. Photodynamic therapy
Activation of photosensitizers with specific wavelength light
leads to energy transfer cascades that ultimately yield cyto-
toxic ROS which can induce local tissue apoptosis and necrosis
[8]. Therefore, harnessing this function mechanism in tumor
therapy provides a safe and controllable way to selectively eradi-
cate tumor with reduced systemic toxicity and side effects on
healthy tissues [9].
Photodynamic therapy is a powerful tool for cancer treat-
ment; however, the lack of stability, solubility and biological
utility limited the application of photosensitizers. Lovell et al.
have created a liposome like nanovesicle by porphyrin bilay-
ers named Porphysome which possess excellent biocompatible,
structure-dependent fluorescence quenching and high absorp-
tion of near-infrared light [10]. In one of his recent published
papers, porphysomes were conjugated folate as targeting-
triggered activatable nano-sized beacons for PDT. Before folate-
mediated endocytosis by tumor cells, the intact porphysomes
could transfer photon energy to thermal energy, but the
nanoparticles would switch back to efficient photodynamic ac-
tivity once they are internalized and disrupted the
nanostructure intracellularly, thus this biocompatible respon-
sive system showed potent clinical application potential [11].
Due to the rarely short half-life of reactive oxygen species
generated based on photodynamic mechanism and the limited
scope it diffuse to, the efficacy of photodynamic therapy highly
depends on the subcellular location of the photosensitizers [12].
Zinc phthalocyanine (ZnPc), a lipophilic photosensitizer which
can localize to membrane and have strong phototoxicity upon
NIR irradiation, is anchored into liposomes with given molar
ratio to construct membrane fusogenic liposomes (MFLs). Com-
pared to the non-fusogenic liposomes, cells treated with MFLs
showed significantly lower viability in the MTT test, which
means photosensitizers localized in the plasma membrane
would induce more membrane disruption and cell death upon
irradiation [13].
Besides its non-invasive and spatiotemporal controllabil-
ity, combining with chemotherapy is helpful to overcome
limitations that are encountered by each modality when used
alone.Multi-drug resistance (MDR) effect is a common symptom
in the course of chemotherapy treatment. To solve such
problem, higher dose andmore frequent administration of che-
motherapy are applied clinically [14]. However, combining PDT
with chemotherapy can figure out the dilemma [15]. ROS pro-
duced by photosensitizers can not only induce tumor cells
apoptosis directly, but also disrupt the cytomembrane and
endolysosomes to prevent the chemo-drugs from being pumped
out by P-glycoprotein (P-gp), etc. and being degraded by enzyme.
A novel drug delivery system was designed by incorporating
the photosensitizer chlorine 6 chemically in the shell and the
chemo-drug doxorubicin physically in the core of D-α-tocopheryl
polyethylene glycol 1000 succinate-poly(lactic acid) (TPGS-
PLA) nanoparticles with a targeting ligand tLyp-1 peptide to
achieve synergetic effect from combination therapy; and pho-
tosensitizer plays a crucial role in the treatment process by
releasing ROS to oxidize cell membrane and degradation-
related enzymes.The effective anti-tumor efficiency has been
proved by the longer survival time in the in vivo tumor-
bearing mice test [16].
3.2. Photothermal therapy
The disordered and irregular vasculature of tumor tissue leads
to lower pH and oxygen level within tumor environment, which
makes tumor more sensitive to hyperthermia than normal
tissues.When temperature rises up to 40 °C ~ 45 °C, tumor cells
would undergo mitochondrial swelling, protein denaturation
and membrane rupture, etc, and yet, normal tissues expo-
sure to this temperature range for one hour, cells do not
observed significant injury [17].
There are several nanomaterials that could respond to near
infrared (NIR) and transform light energy into thermo, which
includes gold-based materials (like Au nanoshell, Au nanorod,
Au nanocage, etc.), carbon-based materials (including carbon
nanotube, CNT and graphene oxide, GO) and CuS-related ma-
terials [18]. Among these responsive materials gold
nanoparticles achieved wide investigation due to their excel-
lent light energy to heat transfer efficiency and inertness. Gold
nanoparticles can strongly absorb light from NIR region through
localized surface plasmon resonance (LSPR) and release the
amount of heat for the ablation of surrounding cells [19].
Graphene oxide possesses special surface properties and su-
perior photo-thermal conversion efficiency,whichmakes it often
serves as platforms for combing other diagnosis agents or drugs
via either covalent or non-covalent conjugation [20]. Both Au
nanoparticle and GO possess excellent PTT efficacy; what if
both of them were integrated into one platform? One article
has seededAu onto GO surface through redox reaction and then
a NIR dye Cy5.5 labeled-matrix metalloproteinase-14 (MMP-
14) peptide substrate (CP) was conjugated onto the GO/Au
complex to form a fluorescence-guided photothermal therapy
system (CPGA). Before CPGA arrived in the tumor region, the
fluorescence signal of Cy5.5 was quenched by Au nanoparticles
via surface plasmon resonance, but upon degradation of the
peptide by the MMP-14, an endopeptidase that is overexpressed
in tumor microenvironment, strong fluorescence signal would
boost, which can analyze the accumulation behaviors at tumor
region and guide the subsequent photothermal therapy as well.
The laser irradiation density is relatively low (0.75 W cm−2), but
the tumors were efficiently ablated after systemic adminis-
tration [21].
Although Au nanoparticles have an outstanding perfor-
mance in photothermal therapy, there are still several flaws
that restricted their further clinical application, such as the NIR
absorbance peak of Au nanoparticles which is related to the
particle size and morphology [22]; and after a long period of
laser irradiation the Au nanoparticles’ NIR absorbance peak
would diminish due to the “melting effect” [23], which weak-
ened their conversion efficiency. In the recent years, copper-
based semiconductors have drawn attention as biocompatible,
low cost, low cytotoxic photothermal agents. The NIR
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absorption of Copper sulfide stems from d-d transition of Cu2+
ions, which leads to a relatively higher NIR region absorption
(~900 nm) than Au nanoparticles, and this region is more suit-
able for in vivo application [24]. Furthermore, CuS nanoparticles
are not affected by the particle size and shape, and have no
“melting effect” phenomenon. To further improve the thera-
peutic effects from PTT, the combination of both PTT and
chemotherapy has attracted increasing attention. Photother-
mal agent CuS and chemo-drug doxorubicin (DOX) integrated
into a thermosensitive composite MEO2MA@MEO2MA-co-
OEGMA (G) to fabricate an on-demand drug release and
photothermal therapy system G-Cus-DOX. Because the low criti-
cal solution temperature (LCST) of MEO2MA@MEO2MA-co-
OEGMA is 42 °C, once G-CuS-DOX is exposed to NIR laser at
915 nm, the boosted thermal energy would ablate the sur-
rounding tumor cells and the high temperature can melt the
MEO2MA@MEO2MA-co-OEGMA for the release of DOX [25].
Given the working mechanisms of photodynamic therapy,
there are three prerequisites to be satisfied: light, photosen-
sitizers and oxygen. Hence, sufficient oxygen content is an
indispensable element for an optimal efficacy. However, Pho-
tothermal therapy (PTT) turned photon energy into substantial
heat diffused to the tissues nearby, so that PTT is indepen-
dent from oxygen concentration within tumors, which offered
an alternative way to excise the deeper core of solid tumor [26].
Thus, it is meaningful to compare the two different modali-
ties: PDT and PTT. The unique properties of liposome like
porphyrin bilayers developed by Gang Zheng group provide the
opportunity to directly compare PDT and PTT using matched
light doses andmatched porphyrin photosensitizer doses (when
the photosensitizer porphyrin were encapsulated in the intact
nanostructure there will be no PDT but only PTT; once the
nanostructure is not existent, the effective PDT of porphyrin
would be recurrent).The treatment scheme is shown in Table 1.
To investigate PDT and PTT in tumor hyperopia and hypoxia
conditions in vivo, they developed a multi-pronged approach
to generate tumor hypoxia and hyperopia in vivo in single
mouse. After systematic treatment and tumor volume mea-
surement, the results showed that (1) the tumors receiving
photofrin PDT under hyperoxic conditions showed exten-
sively damaged areas but tumor remained unaffected when
PDT was conducted under hypoxia conditions, which means
PDT efficacy occurred with sufficient oxygen supply within
tumor but not in a hypoxia condition; (2) the tumors in both
hyperoxic and hypoxic conditions were ablated by the heat fol-
lowing porphysome PTT showing that PTT is an alternative
phototherapy that remains effective even under hypoxia
conditions.
3.3. Light-triggered drug delivery
Except for the two strategies mentioned above, light-sensitive
materials have gained great attention in recent decades.Variety
of mechanisms that can cause light-triggered cargoes re-
leased from nanocarriers have been exploited for designing
light-responsive systems, including photo-isomerization, photo-
crosslinking, photosensitization-induced oxidation, light-
triggered switch in polarity, photo-decrosslinking or photo-
degradation of the polymer backbone [27].
Most photosensitizers used for PDT are activated by light
from 600–700 nm, which have a limited penetration depth in
live tissues. Interestingly, upconversion materials can absorb
light from more than 800 nm but emit visible or NIR light with
narrow spectrum bandwidth. To combine chemotherapy and
PDT in upconversion nanoparticles (UCNP) platform [28], a new
multifunctional UCNPs systemwas fabricated by loading UCNPs
with mPEG-COOH, photosensitizer Ce6 and ROS-cleavable
thioketal-conjugated camptothecin (CPT). Under 980 nm laser
irradiation, UCNPs can convert light to 645–675 nm region,which
excited the loaded photosensitizers and then the released ROS
would be used to photodynamic therapy and cleave the
thioketal linker to release CPT for chemotherapy, simultane-
ously. Together, the activated Ce6 has a fluorescence emission
that can be exploited to fluorescence imaging [29].
Compared with small organic molecule dyes, the back-
bone of conjugated polyelectrolytes (CPEs) has plenty of light-
absorbing units, which featured high absorption coefficients
and fluorescence under laser irradiation [30]. Combining CPEs
that can generate ROS [31] with thioketal groups that can be
readily cleaved by ROS and anticancer drug DOX in single on-
demand drug release system generated a light-triggered ROS-
sensitive drug delivery system. Under illumination, ROS
generated by CPEs causes Dox release through the cleavage of
the linker, thus the delivery system can implement PDT and
chemotherapy effectively and has an on-demand responsive
feature [32]. Nanotechnologies improved the pharmacokinet-
ics of several traditional chemotherapy drugs like DOX and PTX;
however, encapsulating drugs inside carriers result in the in-
efficient intracellular drug release and that remains the rate-
limiting step in reaching the drug therapeutic window. To fix
that awkward nut, responsive release systems seem like a rea-
sonable solution. Arylboronic ester is another ROS sensitive
linker except for the thioketal group, and it is well studied for
imaging and targeting of tumor cells. Making use of arylboronic
ester fabricated an ROS triggering nanosystem, and this system
was assembled from amphiphilic polymer composed of D-α-
tocopherol polyethylene glycol 1000 succinate (TPGS), hyaluronic
Table 1 – Treatment scheme of PDT and PTT.
PDT (porphyrin molecules) PTT (porphysome)
Porphyrin dose 10 mg/kg
Wavelength 635 nm 671 nm
Light power 200 mW (5 min) 200 mW (5 min) 750 mW (85 s)
Light dose 100 J/cm2
Oxygen level Hyperoxia/hypoxia
Note: Comparing PDT (porphyrin molecules) with PTT (porphyrin bilayers) with matched light dose and matched photosensitizers dose (the
light power is different: 200 mW for PDT, 750mW for PTT, but the light dose is exactly same).
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acid (HA) and arylboronic esters, and the in vitro drug release
assay showed that the drug concentration (DOX) can rise rapidly
to reach the therapeutic concentration under illustration.
3.4. Light in theranostics
Integrating imaging functionality into therapeutic proce-
dures could be advantageous to therapy selection, objective
response monitoring and follow-up therapy planning based on
the specific molecular characteristics of diseases [33], which
could greatly enhance the safety and efficacy in treatment
process.
Taking advantage of positron emission tomography (PET)
imaging to monitor and quantitatively analyze the cargos and
localization of drug delivery [34] systems (DDS) is meaning-
ful to optimize therapeutic regimen and gain individualized
medicine [35]. Attaching radio-metal onto gold nanoparticles
via metal chelator is the most common way to integrate PET
imaging to GNPs; however, this pattern may influence the
surface properties of the GNPs and limit their ability to load
other targeting or therapeutic agents. It is feasible to inte-
grate 64Cu to PEG-stabilized Au NPs via chemical reduction of
64CuCl2 under mild reaction conditions. The in vivo experi-
ments proved that the stability of radiochemical and the
noninvasive PET imaging provide an accurate and sensitive lo-
calization of Au NPs. Thus, 64Cu radio-labeling protocol could
be applied to develop a visualized photothermal therapy and
that is very meaningful to clinical application [36].
Photosensitizes could be multifunctional in both therapy
and diagnosis since upon illumination, they would generate
ROS and emit strong fluorescence simultaneously without ad-
ditional fluorescent dyes [37]. However, most of photosensitive
materials are hydrophobic and has low selectivity to target sites
[38]. Via Michael-type polymerization [39] the pH-responsive
block copolymermicelles were prepared using hydrophilic MPEG
and poly(β-amino ester). Subsequently, the hydrophobic pho-
tosensitizers Protoporphyrin IX were loaded into micelles by
solvent evaporation method and the loading efficiency could
reach up to 70–80% when the Protoporphyrin IX content in the
polymeric micelles is less than 10 wt%. In tumor bearing mice,
thesemicelles showed clear fluorescent imaging and the tumors
are eradicated completely [40]. Indocyanine green (ICG) is an
NIR dye for clinical application approved by the FDA and it can
not only transfer energy from light to ROS for PDT [41], but can
also raise local temperature for PTT; therefore, ICG could serve
as a desired agent for theranostic. Employing 4T1 breast cancer
cells in subcutaneously incubated nude mice as the animal
modal, free ICG and HSA-ICG NPs were intravenously in-
jected respectively. Fluorescent signals from injected free ICG
mice mainly observed in liver and completely disappeared after
24 h postinjection; in contrast, in the case of HSA-ICG NPs mice,
strong fluorescent signals have been detected within tumor
region and 7 days after injection signal still could be ob-
served [42].
4. Magnetically responsive system
Among the broad spectrum of nanoscale materials being in-
vestigated for biomedical application, magnetic nanoparticles
(MNPs) have attracted significant attention due to their
intrinsic magnetic properties, which enable tracking through
radiology and magnetic resonance (MR) imaging [43]. More-
over, in contrast to optical-dependent therapy that cannot be
applied unless the penetration depth is less than centime-
ters,magnetic fields, particularly with frequencies below 400 Hz,
are not significantly absorbed by tissues, allowing remote imple-
mentation without physical contact [44]. In response to different
types of magnetic field, permanent magnetic (PMF) or alter-
nating magnetic field (AMF), MNPs would generate various
treatment modalities, which can be applied to magnetic-
triggered drug delivery, hyperthermia and imaging-guided
therapy [45].
4.1. Magnetic field-assistant drug delivery
Although magnetic field is always served as an imaging
tool clinically, it is also extensively applied in other scenarios
[46].
Since magnetite Fe3O4 and maghemite γ-Fe2O3 are supe-
rior to other metal oxide nanoparticles because of their
biocompatibility and stability, making them the most com-
monly employed MNPs for biomedical applications by far [47],
magnetic-responsive nanocarriers generally incorporate the
bioactive carriers along with a magnetically active compo-
nent, either magnetite (Fe3O4) or maghemite (γ-Fe2O3), in a
pharmaceutically stable formulation [48]. To avoid limita-
tions of physical entrapment, there are some preparations using
covalent-bond to connect magnetic nanocarriers and drugs for
improved drug loading and higher accumulation in target sites.
For example, Hua et al. framed a novel core-shell shaped drug
nanocarrier using the polymer poly[aniline-co-N-(1-one-
butyric acid) aniline] (SPAnH) coated on Fe3O4 cores to form
magnetic nanoparticles (MNP) and the chemotherapeutic agent
BCNU was immobilized successfully on MNPs by covalent
bonding between the −NH of BCNU and the −COOH of MNPs.
In the presence of magnetic field beneath the culture plates,
the MNPs uptake of C6 cells was notably increased and the IC50
of bound-BCNU was lowered to 16.1 ug/mL, hence, it is pos-
sible to use lower concentration of drugs to provide more
efficient tumor suppression, concurrently, reducing the like-
lihood of adverse systemic effects [49].
Recently Choi et al. reported a block copolymer
poly(ethylene-oxide)-poly(propylene-oxide)-poly(ethylene-
oxide) (PEO-PPO-PEO) and this triblock polymer has a range
of critical micellization temperature (CMT) for volume/
hydrophobicity trisection [50]. Inspired by this featured
temperature sensitive copolymer, Liu et al. fabricated a mag-
netic triggered drug release system with a collapsible magnetic
core of iron oxide immersed in a water solution of vitamin
B12 and a fast-breathing nanosized two-layer shell of ther-
mally responsive PEO-PPO-PEO polymer, and a cross-linked
outer shell that stabilizes the nanoshell while maintaining
the CMT. Upon exposure to external-placed magnetic field,
the nanocapsule will be heated and volume will change;
finally, the outer shell will be disrupted and drug will burst
out [51].When submitted to high frequency alternating mag-
netic field (HAMF), the superparamagnetic cores of nanocarriers
will generate heat which can boost drugs release, and this
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phenomenon has been denominated as the magnetic hyper-
thermia effect [52].
Magnetotactic bacteria are a particular sort of microorgan-
isms that can orient and migrate along the geomagnetic filed
lines [53]. This distinctive feature is based on bacterial
magnetosomes, which are the magnetic inclusions produced
by magnetotactic bacteria with core-shell structure [54]. The
main chemical composition of magnetosomes are the mem-
brane enclosed inorganic crystals of magnetite or greigite that
make magnetotactic bacteria more sensitive to magnetic field
[55] and that makes bacterial magnetosomes possess unique
advantages including superparamagnetic property, uniform par-
ticle size, fine dispersion and large specific surface area, all of
these properties demonstrating that bacterial magnetosomes
could be served as potential magnetic drug carriers [56]. Fur-
thermore, bacterial magnetosomes can overcome the deficiency
of artificial synthetic magnetic nanoparticles when applying
to targeted drug delivery, such as low drug loading capability,
agglomeration tendency and difficulties in size or shape control.
The mechanism of bacterial magnetosomes used for target-
ing therapy is that magnetosomes complex nanoparticle loaded
with drugs can locally target lesion site under an external mag-
netic field. In these magnetic drug targeting strategy,
magnetosomes used as the carriers for the chemotherapeu-
tic agent, gene vaccine or contrast agent would centralize at
the desirable site, and therefore increasing drug concentra-
tion at the targeted site, which minimizes the distribution in
healthy tissues [57]. Bacterial magnetosomes have novel mag-
netic, physical, and other properties that can and have been
developed and investigated in a variety of scientific, medical
and commercial applications. However, despite the fact that
bacterial magnetosomes hold tremendous potential as drug car-
riers, there are still many obstacles that may restrain the clinical
application for bacterial magnetosomes. Alphandéry et al. ex-
tracted bacterial magnetite magnetosomes chains fromAMB-1
magnetotactic bacteria and incubated with suspension con-
taining MDA-MB-231, it was demonstrated that up to 100% of
cells were destroyed when exposed to an alternative mag-
netic field of frequency 183 kHz and field strengths of 20, 40,
or 60 mT compared with cells incubated in the absence of an
alternative magnetic field, which the viability of these cells still
remained high. The anti-tumor activity of these chains of
magnetosomes was demonstrated further by showing that they
can be used to fully eradicate a tumor xenografted under the
skin of a mouse. When comparing extracted chains of
magnetosomes with various other materials obtained from dif-
ferent approaches, the higher efficiency of magnetosomes may
be explicated to the following factors: higher specific absorp-
tion rate and more efficient penetration within cell membrane
under the application of the alternative magnetic field [58].The
effects of magnetic trapping of mitochondria using aptamer
conjugated to bacterial magnetic nanoparticles that allowed
targeting of the mitochondrial cytochrome c in the treat-
ment of cancer cells has been reported recently, which offers
a new approach for targeted cell therapy [59]. Tang et al. sug-
gested that the bacterial magnetite particles can be used as a
novel and efficient gene vaccine delivery system. In their study,
magnetosomes were used as carriers of a recombinant DNA
composed of a secondary lymphoid tissue chemokine, human
papillomavirus type E7 (HPV-E7) and Ig-Fc fragment (pSLC-E7-Fc).
Subcutaneous injection of BMP-V with a 600-mT static mag-
netic field exposure for 10 min elicited systemic HPV-E7-
specific immunity leading to significant tumor inhibition in a
mouse model [60].
4.2. Magnetic hyperthermia
While MNPs are accumulating in the tumor site, permanent
magnetic field (PMF) or alternating magnetic field (AMF) could
be taken into consideration subsequently, according to the
mechanism of the design idea. Among the activation ap-
proaches, AMF is preferred because of its unique mechanism
to actuate localized hyperthermia based on the Néel and Brown-
ian relaxation mechanism [61]. Therefore, combining this
property with thermal-sensitive or other functional
nanocarriers, a broad range of actuation mechanisms for on-
demand drug release has been developed [62].
Magnetic-induced hyperthermia and photodynamic therapy,
each single treatment, could slightly inhibit tumor growth,while
their combination may lead to complete tumor regression. To
encapsulate a high concentration of magnetic nanoparticles
with liposome core and bringm-THPC, a photosensitizer already
used clinically, into the lipid-bilayers, yield liposomes with
highly satisfactory ratios of two components.Then the double
cargo translated into dual-functionality, generating singlet
oxygen by laser excitation and thermal production under al-
ternating magnetic field stimulation, which coupled PDT to
hyperthermia.The in vivo rodent model tests have shown total
solid-tumor ablation, which verified the synergistic potential
of a combined therapy [63].
Therapeutic resistance is a major problem in chemo-
therapy and the problem also exists in hyperthermia therapy.
Heat-treated cells can acquire resistance to thermal stress
readily and obviously increase cells’ survival rate, which is
termed thermoresistance [64]. Integrating heat shock protein
(Hsp) inhibitor [65] and heat generation moiety MNPs to single
magnetic triggered nano platform, Yoo et al. fabricated a
resistance-free apoptosis-inducing magnetic nanoparticle
(RAIN), which can promote thermoresistance-free apoptosis [66].
Temperature needed to induce cell apoptosis is believed to
be above 43 °C due to the energy dissipation in alternating mag-
netic field [67], but the heat removal rate by conduction is
notably faster than the energy dissipation velocity by MNPs;
moreover, Gordon suggested that the cell membrane would act
as an insulator during the thermal conduction [68]. Thus, it is
reasonable to fabricate cell targeting MNPs that is able to be
uptaken by specific type cells readily and then put them under
alternating magnetic field to burn the cells. Results of cell as-
sociated experiments showed that MNPs linked epidermal
growth factor receptor (EGFR) induced up to 99.9% reduction
in cell viability with a negligible temperature rise [67].
4.3. MRI-guided therapy
Organic dyes can be introduced to nanoplatform for fluores-
cent imaging; however, the limited penetrating depth and
readily fluorescence quenching constrict their application. In
contrast, magnetic resonance imaging (MRI) can penetrate
tissues deeper andmore stable, so that MRI based nanoparticles
is widely investigated in precisely detecting diseases at early
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stage and tracking the biodistribution of nanocarriers in vivo;
furthermore, the non-invasive nature and excellent spatial reso-
lution promote its application in clinical [69].
Generally, MRI has two modes, namely T1- and T2-weighted
MRI, and the former is favored in clinical as they provide posi-
tive signals [70], and paramagnetic gadolinium andmanganese
are commonly used contrast agents for T1 weighted MRI [71].
Porphysome created by MacDonald et al. are inherently
multimodal; it is capable of directly chelating metal ions like
copper and manganese so they can be embedded in the
nanoplatform without exogenous components. Thus the in-
sertion of Mn into porphysome can generate MRI sensitivity
at a comparable level to the clinically used Gd-DTPA, while re-
taining high photothermal efficiency [72].
Iron oxide like super-paramagnetic γ-Fe2O3 is widely known
for T2-weighted negative contrast, and compared with noble
metals like Mn2+ and Gd3+, the toxicity of Fe3O4 is negligible and
it can provide highly sensitive imaging as well [73].
Superparamagnetic iron oxide nanoparticles (SPIONs) can serve
as contrast agents for T2-weighted imaging and according to
the static dephasing regime (SDR) theory; it is reasonable to
tailor nanoparticle size within a range for maximizing the
relaxivity; however, SPIONs with diameters approaching the
optimal size often become permanently magnetic [74], result-
ing in uncontrolled aggregation that diminishes relaxivity and
substantially reduces the SPION’s ability to reach target sites.
Coating SPIONs with a hyperbranched polyglycerol substi-
tuted with a varying number of octadecyl chains (HPG) to form
nanoclusters,which can elegantly solve the aggregation problem
and achieve high relaxivity of 719 mM−1 s−1 that is close to the
theoretical maximal limit [75].
There is another strong point of iron nanoparticle. Studies
have confirmed the feasibility of T1/T2 dual-modality con-
trast agents based on Fe3O4 NPs only which means that iron-
based MRI can combine the advantages both of T1 and T2
imaging modes [76]. Polydopamine nanospheres (PDAs) are ef-
fective photothermal therapy agents with high photo-to-
heat conversion efficiency and excellent biodegradability, and
previous studies have shown that PDAs can provide anchor sites
for iron ions result from their strong chelate ability; thus, to
combine MRI-guided photothermal nanoplatform is feasible.
5. Ultrasonic-responsive
Similarly, ultrasound has a number of attractive characteris-
tics as a trigger for drug delivery. It is appealing because of its
non-invasiveness, the absence of ionizing radiations, and the
facile regulation of tissue penetration depth by tuning fre-
quency, duty cycles and time of exposure [77]. Additionally, it
could reach deeper sites into the body than light-trigger (except
for NIR-responsive) and the sonoporation phenomenon could
act on the cell membrane that facilitate therapeutic mol-
ecules entrance into cells, to some extent, could reverse the
multi-drug resistance of tumor cells [78].
5.1. Ultrasound in responsive system
Applying ultrasound technology in designing delivery system
mainly is based on two physical mechanisms: heat and cavi-
tation. By setting up high intensity focused ultrasound (HIFU)
outside of the desired site, the localized temperature can be
raised mildly which induced tumor cells apoptosis and ne-
crosis. Au nanocages (AuNCs) is one of the hollow structure
nanoplatforms; besides photothermal effect triggered by NIR
laser, HIFU can directly transfer acoustic energy in the focal
site to raise the temperature rapidly [79]. Thus, encapsulat-
ing anticancer drugs and phase-changematerials (PCMs), which
could convert to liquid state when temperature rises up to 39 °C,
into the hollows of AuNCs to form an ultrasound responsive
drug release system. Under ultrasound or NIR laser, the PCM
inside the cages would be melted by AuNCs generated heat and
then the fluid PCM would escape from the interiors of
nanocages through small pores on the surface and release the
encapsulated small molecule drugs into the surrounding
medium [80].
Beside serving as heat producer under HIFU, when exposed
to the exerted cycles of negative and positive pressure,
microbubble would become oscillatory and high acoustical pres-
sure could induce more drastic microbubble oscillations, which
results in microbubble destruction and such property is named
inertial cavitation [81]. Liang et al. successfully fabricated a tem-
perature sensitive cerasomes which includes cerasome-
forming lipid, DPPC, DSPE-PEG and a temperature sensitive
phosphocholine MSPC based on Bangham method in combi-
nation of sol–gel reaction and self-assembly process. The
thermosensitive cerasomes exhibit excellent biocompatibil-
ity and long blood circulation time (half-life > 8.5 h) than
conventional temperature sensitive liposomes [82]. Low fre-
quency ultrasound (LFUS), which is also termed as unfocused
ultrasound, has been used to enhance biological membranes
permeability and LFUS is more effective than high frequency
ultrasound in releasing DOX from liposomes [83]. Loading an-
ticancer agent cisplatin into the nano sterically stabilized
liposomes (nSSL) and injecting into tumor-bearing mice in-
traperitoneally, after accumulating in tumor site by EPR effect,
LFUS was settled externally to the abdominal wall and drug
release was quantified. The results showed that nearly 70%
cisplatin was released in tumor under the exposure to LFUS;
however, the matched group that was not exposed to LFUS had
less than 3% release [84].
Mechanisms beyond the ultrasound-based cell uptake en-
hancement were widely studied: under low acoustic pressures
cell endocytosis is enhanced, since higher acoustic pressures
favor uptake via membrane pores [85]. Hence, it is important
to understand whether loading nanoparticles into microbubbles
or when they are physically mixed with the microbubbles can
enhance the delivery across cellular membrane. In order to com-
plete this task, two different nanoparticles were used, one is
fluorescent polystyrene nanospheres, it were chosen as model
nanoparticles as they are highly fluorescent, another one is
fluorescently labeled mRNA-lipoplexes serve as therapeuti-
cal nanoparticles and there are two options whether combine
microbubble with nanoparticles or not. The results of the in
vitro experiments elucidated that ultrasound can improve the
intracellular delivery of large nanoparticles like mRNA-
lipoplexes only when these were loaded into microbubbles and
the ‘co-administration mode’ may only be useful when using
small drug molecules since they can readily cross the mem-
brane pores generated by cavitation [86].
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5.2. Ultrasound-guided theranostics
Ultrasound has been applied in medical imaging for a long
history. Ultrasound image is created by ultrasound waves re-
flected by tissues with a density different from the surrounding
medium; however, the contrast may not be obvious enough due
to the compressibility of vasculature or other blood contain-
ing tissues, so that to enhance the imaging quality contrast
agent is indispensable.
Microbubbles, hollow particles that contain gas, are applied
as an ultrasound contrast agent recently since they possess
acoustic characteristics different from plasma. Calcium car-
bonate minerals are insoluble at neutral pH but they can
produce carbon dioxide in acidic conditions rapidly. In addi-
tion, the pH value of intracellular compartments such as
endosomes (pH 5-6) and lysosomes (pH 4-5) are distinct to the
extracellular environment, carbon dioxide release can only be
triggered after being endocytosed by tumor cells and calcium
carbonate is almost completely decomposed to carbon dioxide
at pH 5 [87–89]. Hence, encapsulating fine-grained calcium car-
bonate inside a rabies virus glycoprotein (RVG) modified
Poly(D,L-lactide-co-glycolide) (PLG) nanocomplex via W/O/W
double emulsion method can create gas-generating polymer
nanoparticles (GNPs) and these GNPs are expected to induce
necrotic cell death by releasing gas bubbles under ultra-
sound trigger. Injected into tumor-bearing mice intravenously,
carbon dioxide generated from GNPs can effectively reduce the
tumor size upon ultrasound applied extracorporeally [90].
Traditional ultrasound imaging has rarely been employed
for cancer therapy because the size of microbubbles (3 to 10 μm
in diameter) makes the permeation of tumor microvessels low
probability [90]. Porphyrin-lipid possesses unique multimodal
imaging features intrinsically, using porphyrin-lipid to form an
organic shell around perfluorocarbon gas fabricated porphy-
rin microbubbles (pMBs). On exposure to low frequency
ultrasound, the microbubble consists of a bacteriochlorophyll–
lipid shell around a perfluoropropane gas burst and form
smaller nanoparticles that possess the same optical proper-
ties as the original microbubbles.
The pMBs peak size distribution was between 2 and 8 μm
by volume with 99.9% < 10 μm by number, after low fre-
quency ultrasound pulse, the pMBs burst into pNPs which
polydisperse in size between 5 and 500 nm with 99% of pNPs
in all samples having dimensions of <500 nm [91]. Encapsu-
lating low boiling point perfluorocarbon, a thermosensitive
liquid, to vaporize as gas, has been widely exploited; however,
instead of using gaseous or perfluorocarbon, liquid H2O2 can
be easily introduced by the hydrophilic core of polymer and
the H2O2 plays a crucial role in concurrently providing O2 for
echogenic reflectivity and •OH as the therapeutic reactive
oxygen species (ROS). Meanwhile, encapsulating H2O2 in the
hydrophilic core with Fe3O4 nanoparticles packed in the shell
of the polymersome, once exposed to ultrasound, the encap-
sulated H2O2 was liberated and moved through the disruption
of PLGA polymersome to react with Fe3O4 thus yielding •OH
following a Fenton reaction [92].
6. Challenges and outlooks
Stimuli-responsive drug delivery systems have a rapid prog-
ress in the past few decades. These strategies exhibit
tremendous therapeutic and detection potency for cancer at
both research and clinical levels. Nanomaterials, including poly-
mers, lipids and inorganic materials, which were introduced
into stimuli responsive system, hold incredible promise in over-
coming the limitations and drawbacks of conventional drug
delivery mode.Additionally, they offered unprecedented control
over spatiotemporal drug release and delivery profiles leading
to superior in vitro and in vivo theranostic efficiency.
Despite emerging progress made in external stimuli-
responsive drug delivery research, there remain many
challenges that need to be addressed; some of them have been
listed in Table 2. Light-responsive systems need illumination
to activate the light-sensitive materials; however, not all regions
of the spectrum are appropriate for clinical use, which is also
the major drawback of light treatments. Light from the
ultraviolet-visible (UV) region always has a poor penetration
ability for 10 mm atmost due to the strong absorption and scat-
tering of skin, blood and soft tissues [77]. Except for the light
wavelength problem of light-based treatments, laser power
density is also an important factor that should be consid-
ered. It’s considered that laser power density beyond 1W cm−2
is harmful to health. Yet such dilemma could be avoided by
using photosensitive groups that respond to higher wave-
length like near-infrared (NIR) and that have less absorption
and scattering but deeper penetration capability for almost 1 cm
and minimal photo-toxicity. It is also feasible to apply two-
photon technology, which is possible to shift the UV light source
to reach NIR. Consequently, light-responsive systems are potent
which is promising for clinical applications.
Table 2 – The summary of the advantages and limitations of light-responsive systems, magnetic field-responsive
systems and ultrasound-responsive systems.
Light-responsive systems Magnetic field-
responsive systems
Ultrasound-responsive
systems
Advantages (compared
with traditional DDS)
Spatiotemporally controllable
Noninvasive and absence of ionizing radiations
High image resolution
Combine therapy and diagnosis in one platform, etc.
Limitations Light wavelength and power density problem Relatively costly Microbubbles has a short half-
life in circulation
The degradation problem of contrast agent Possibly because of metastatic
dissemination
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Magnetic field is widely used in clinical application; it is a
relatively mature technology but also has shortcomings like
the degradation problem of noble-metal contrast agents and
the relatively higher treatment cost than other diagnosis tools
like CT imaging.
To date, a major disadvantage of microbubbles as drug car-
riers is their relatively large size (1–6 μm). Due to this feature,
microbubbles have a rather short half-life.Upon injection of the
microbubbles, they will circulate for a few times, but will in-
evitably get stuck in the lungs where gas exchange occurs [81].
Consequently, microbubble ultrasound triggered drug delivery
will bemainly restricted to cardiovascular targets and to tumor
endothelia. More importantly, ultrasound-mediated enhance-
ment of vessel permeability can also be the cause of possible
drawbacks such as metastatic dissemination. Fortunately, this
difficultymaybeovercomeby thedevelopmentofperfluorocarbon
(PFC) nanoemulsionswhichare able to convert intomicrobubbles
under the activation of therapeutic ultrasound.The bubbles are
formed through acoustic droplet vaporization and are sub-
jected to cavitation, thuspromoting cellularuptakeand/or release
of the entrapped drugs in the tumor site [77].
Further fundamental understanding of the spatial and tem-
poral patterns offers essential criteria for designing more
effective and precise delivery vehicles. Meanwhile, more spe-
cific designs should be taken into account for enhancing
delivery efficacy. Further, eventual clinical translation of stimuli-
responsive drug delivery requires comprehensive evaluation
of biocompatibility of relevant formulations and there is a long
way to go.
Acknowledgments
This work was supported by National Natural Science Foun-
dation of China (81373353), Shanghai Science and Technology
Committee (13NM1400500), and Program for New Century Ex-
cellent Talents in University (NCET-12-0130).
R E F E R E N C E S
[1] Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for
controlled drug delivery. Nanoscale 2014;6:12273–12286.
[2] Khadka P, Ro J, Kim H, et al. Pharmaceutical particle
technologies: an approach to improve drug solubility,
dissolution and bioavailability. Asian J Pharm Sci 2014;9:304–
316.
[3] Toh MR, Chiu GNC. Liposomes as sterile preparations and
limitations of sterilisation techniques in liposomal
manufacturing. Asian J Pharm Sci 2013;8:88–95.
[4] Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric
nanocarriers for the controlled transport of active
compounds: concepts and applications. Adv Drug Deliv Rev
2012;64:866–884.
[5] Liu Y, Wang W, Yang J, et al. pH-sensitive polymeric micelles
triggered drug release for extracellular and intracellular
drug targeting delivery. Asian J Pharm Sci 2013;8:159–167.
[6] Lehner R, Wang X, Wolf M, et al. Designing switchable
nanosystems for medical application. J Control Release
2012;161:307–316.
[7] Chen Q, Ke H, Dai Z, et al. Nanoscale theranostics for
physical stimulus-responsive cancer therapies. Biomaterials
2015;73:214–230.
[8] Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic
therapy. J Natl Cancer Inst 1998;90:889–905.
[9] Master A, Livingston M, Sen Gupta A. Photodynamic
nanomedicine in the treatment of solid tumors:
perspectives and challenges. J Control Release 2013;168:88–
102.
[10] Lovell JF, Jin CS, Huynh E, et al. Porphysome nanovesicles
generated by porphyrin bilayers for use as
multimodal biophotonic contrast agents. Nat Mater
2011;10:324–332.
[11] Jin CS, Cui L, Wang F, et al. Targeting-triggered porphysome
nanostructure disruption for activatable photodynamic
therapy. Adv Healthc Mater 2014;3:1240–1249.
[12] Kou L, Sun J, Zhai Y, et al. The endocytosis and intracellular
fate of nanomedicines: implication for rational design. Asian
J Pharm Sci 2013;8:1–10.
[13] Kim J, Santos OA, Park JH. Selective photosensitizer delivery
into plasma membrane for effective photodynamic therapy.
J Control Release 2014;191:98–104.
[14] Shapira A, Livney YD, Broxterman HJ, et al. Nanomedicine
for targeted cancer therapy: towards the overcoming of drug
resistance. Drug Resist Updat 2011;14:150–163.
[15] Wong BS, Yoong SL, Jagusiak A, et al. Carbon nanotubes for
delivery of small molecule drugs. Adv Drug Deliv Rev
2013;65:1964–2015.
[16] Jiang D, Gao X, Kang T, et al. Actively targeting d-alpha-
tocopheryl polyethylene glycol 1000 succinate-poly(lactic
acid) nanoparticles as vesicles for chemo-photodynamic
combination therapy of doxorubicin-resistant breast cancer.
Nanoscale 2016;8:3100–3118.
[17] Reinhold HS, Endrich B. Tumour microcirculation as
a target for hyperthermia. Int J Hyperthermia 1986;2:111–
137.
[18] Kim H, Chung K, Lee S, et al. Near-infrared light-responsive
nanomaterials for cancer theranostics. Wiley Interdiscip Rev
Nanomed Nanobiotechnol 2016;8:1022–1098.
[19] Park JH, Von Maltzahn G, Ong LL, et al. Cooperative
nanoparticles for tumor detection and photothermally
triggered drug delivery. Adv Mater 2010;22:880–885.
[20] Ji H, Sun H, Qu X. Antibacterial applications of graphene-
based nanomaterials: recent achievements and challenges.
Adv Drug Deliv Rev 2016;25:857–861.
[21] Gao S, Zhang L, Wang G, et al. Hybrid graphene/Au
activatable theranostic agent for multimodalities imaging
guided enhanced photothermal therapy. Biomaterials
2015;79:28–54.
[22] El-Sayed SL, Shape AM. and size dependence of radiative,
non-radiative and photothermal properties of gold
nanocrystals. Int Rev Phys Chem 2000;19:409–453.
[23] Zha Z, Yue X, Ren Q, et al. Uniform polypyrrole nanoparticles
with high photothermal conversion efficiency for
photothermal ablation of cancer cells. Adv Mater
2013;25:777–782.
[24] Tian Q, Tang M, Sun Y, et al. Hydrophilic flower-like CuS
superstructures as an efficient 980 nm laser-driven
photothermal agent for ablation of cancer cells. AIDS Care
2011;23:3542–3547.
[25] Meng Z, Wei F, Wang R, et al. Tumor therapy: NIR-laser-
switched in vivo smart nanocapsules for synergic
photothermal and chemotherapy of tumors. Adv Mater
2016;28(2):245–253.
[26] Pang B, Zhao Y, Luehmann H, et al. (64)Cu-Doped PdCu@Au
Tripods: a multifunctional nanomaterial for positron
emission tomography and image-guided photothermal
cancer treatment. Angew Chem Int Ed Engl 1962;1:246–264.
593a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 5 8 5 – 5 9 5
[27] Jhaveri A, Deshpande P, Torchilin V. Stimuli-sensitive
nanopreparations for combination cancer therapy. J Control
Release 2014;190:352–370.
[28] Wang C, Tao H, Cheng L, et al. Near-infrared light induced
invivo photodynamic therapy of cancer based on
upconversion nanoparticles. Biomaterials
2011;32:6145–6154.
[29] Caixia Y, Chunlei Z, Gabriel A, et al. Near-Infrared light
triggered ROS-activated theranostic platform based on
Ce6-CPT-UCNPs for simultaneous fluorescence imaging and
chemo-photodynamic combined therapy. Theranostics
2016;6:456–469.
[30] Duarte A, Pu KY, Liu B, et al. Recent advances in conjugated
polyelectrolytes for emerging optoelectronic applications.
Chem Mater 2010;23:501–515.
[31] Zhu C, Yang Q, Lv F, et al. Conjugated polymer-coated
bacteria for multimodal intracellular and extracellular
anticancer activity. Adv Mater 2013;25:1203–1208.
[32] Yuan Y, Liu J, Liu B. Conjugated-polyelectrolyte-based
polyprodrug: targeted and image-guided photodynamic and
chemotherapy with on-demand drug release upon
irradiation with a single light source. Angew Chem Int Ed
Engl 2014;53:7163–7168.
[33] Ryu JH, Lee S, Son S, et al. Theranostic nanoparticles for
future personalized medicine. J Control Release
2014;190:477–484.
[34] Cutler CS, Hennkens HM, Sisay N, et al. Radiometals
for combined imaging and therapy. Chem Rev 2012;113:858–
883.
[35] Sanjiv Sam G. Molecular imaging of cancer with positron
emission tomography. Nat Rev Cancer 2002;2:683–693.
[36] Sun X, Huang X, Yan X, et al. Chelator-free (64)Cu-integrated
gold nanomaterials for positron emission tomography
imaging guided photothermal cancer therapy. ACS Nano
2014;8:8438–8446.
[37] So Jin L, Kyeongsoon P, Yu-Kyoung O, et al. Tumor specificity
and therapeutic efficacy of photosensitizer-encapsulated
glycol chitosan-based nanoparticles in tumor-bearing mice.
Biomaterials 2009;30:2929–2939.
[38] Niamien KY, Robert G, Eric A. State of the art in the delivery
of photosensitizers for photodynamic therapy. J Photochem
Photobiol B 2002;66:89–106.
[39] Akiyoshi K, Deguchi S, Tajima H, et al. Microscopic structure
and thermoresponsiveness of a hydrogel nanoparticle by
self-assembly of a hydrophobized polysaccharide.
Macromolecules 1997;30:857–861.
[40] Koo H, Lee H, Lee S, et al. In vivo tumor diagnosis and
photodynamic therapy via tumoral pH-responsive polymeric
micelles. Chem Commun (Camb) 2010;46:5668–5670.
[41] Sheng Z, Hu D, Xue M, et al. Indocyanine green
nanoparticles for theranostic applications. Nano Micro Lett
2013;5:145–150.
[42] Sheng Z, Hu D, Zheng M, et al. Smart human serum
albumin-indocyanine green nanoparticles generated by
programmed assembly for dual-modal imaging-guided
cancer synergistic phototherapy. ACS Nano 2014;8:12310–
12322.
[43] Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR
imaging and drug delivery. Adv Drug Deliv Rev 2008;60:1252–
1265.
[44] Karimi M, Ghasemi A, Sahandi ZP, et al. Smart micro/
nanoparticles in stimulus-responsive drug/gene delivery
systems. J Control Release 2016;219:355–368.
[45] Dongwon Y, Jae-Hyun L, Tae-Hyun S, et al. Theranostic
magnetic nanoparticles. Acc Chem Res 2011;44:863–874.
[46] Chenjie X, Shouheng S. New forms of superparamagnetic
nanoparticles for biomedical applications. Adv Drug Deliv
Rev 2013;65:732–743.
[47] Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for
theragnostics. Adv Drug Deliv Rev 2009;61:467–477.
[48] Ajay Kumar G, Naregalkar RR, Vikas Deep V, et al. Recent
advances on surface engineering of magnetic iron oxide
nanoparticles and their biomedical applications.
Nanomedicine (Lond) 2007;2:23–39.
[49] Hua MY, Liu HL, Yang HW, et al. The effectiveness of a
magnetic nanoparticle-based delivery system for BCNU in
the treatment of gliomas. Biomaterials 2011;32:516–527.
[50] Choi SH, Lee JH, Choi SM, et al. Thermally reversible
pluronic/heparin nanocapsules exhibiting 1000-fold volume
transition. Langmuir 2006;22:1758–1762.
[51] Liu TY, Liu KH, Liu DM, et al. Temperature-sensitive
nanocapsules for controlled drug release caused by
magnetically triggered structural disruption. Adv Funct
Mater 2009;19:616–623.
[52] Fortin JP, Wilhelm C, Servais J, et al. Size-sorted anionic iron
oxide nanomagnets as colloidal mediators for magnetic
hyperthermia. J Am Chem Soc 2007;129:2628–2635.
[53] Pan Y, Petersen N, Winklhofer M, et al. Rock magnetic
properties of uncultured magnetotactic bacteria. Earth
Planet Sci Lett 2005;237:311–325.
[54] Okamura Y, Takeyama H, Matsunaga T. Two-dimensional
analysis of proteins specific to the bacterial magnetic
particle membrane from Magnetospirillum sp. AMB-1. Appl
Biochem Biotechnol 2000;84–86:441.
[55] Lefevre CT, Abreu F, Lins U, et al. A bacterial backbone:
magnetosomes in magnetotactic bacteria. In: Metal
nanoparticles in microbiology. Springer: Berlin, Heidelberg;
2011. p. 75–102.
[56] Dutz S, Clement JH, Eberbeck D, et al. Ferrofluids of magnetic
multicore nanoparticles for biomedical applications. J Magn
Magn Mater 2009;321:1501–1504.
[57] Guo L. Bacterial magnetic nanoparticles as drug carriers.
J Mater Chem 2008;18:5993–5997.
[58] Alphandéry E, Faure S, Seksek O, et al. Chains of
magnetosomes extracted from AMB-1 magnetotactic
bacteria for application in alternative magnetic field cancer
therapy. ACS Nano 2011;5:6279–6296.
[59] Choi J, Shin J, Lee J, et al. Magnetic response of
mitochondria-targeted cancer cells with bacterial magnetic
nanoparticles. Chem Commun (Camb) 2012;48:7474–7476.
[60] Tang YS, Wang D, Zhou C, et al. Bacterial magnetic particles
as a novel and efficient gene vaccine delivery system. Gene
Ther 2012;19:1187–1195.
[61] Soukup D, Moise S, Céspedes E, et al. In situ measurement of
magnetization relaxation of internalized nanoparticles in
live cells. ACS Nano 2015;9:231–240.
[62] Shi D, Sadat ME, Dunn AW, et al. Photo-fluorescent and
magnetic properties of iron oxide nanoparticles for
biomedical applications. Nanoscale 2015;7:8209–8232.
[63] Di Corato R, Bealle G, Kolosnjaj-Tabi J, et al. Combining
magnetic hyperthermia and photodynamic therapy for
tumor ablation with photoresponsive magnetic liposomes.
ACS Nano 2015;9:2904–2916.
[64] Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug
resistance in cancer. Nat Rev Drug Discov 2006;5:219–234.
[65] Pan Y, Du X, Zhao F, et al. Magnetic nanoparticles for the
manipulation of proteins and cells. Chem Soc Rev
2012;41:2912–2942.
[66] Yoo D, Jeong H, Noh SH, et al. Magnetically triggered dual
functional nanoparticles for resistance-free apoptotic
hyperthermia. Angew Chem Int Ed Engl 2013;52:13047–
13051.
[67] Creixell M, Bohorquez AC, Torres-Lugo M, et al. EGFR-
targeted magnetic nanoparticle heaters kill cancer cells
without a perceptible temperature rise. ACS Nano
2011;5:7124–7129.
594 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 5 8 5 – 5 9 5
[68] Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia. A
biophysical approach to cancer treatment via intracellular
temperature and biophysical alterations. Med Hypotheses
1979;5:83–102.
[69] Wang Y, Gu H. Core-shell-type magnetic mesoporous silica
nanocomposites for bioimaging and therapeutic agent
delivery. Adv Mater 2015;27:576–585.
[70] Terreno E, Uggeri F, Aime S. Image guided therapy: the
advent of theranostic agents. J Control Release 2012;161:328–
337.
[71] Janib SM, Moses AS, Mackay JA. Imaging and drug delivery
using theranostic nanoparticles. Adv Drug Deliv Rev
2010;62:1052–1063.
[72] MacDonald TD, Liu TW, Zheng G. An MRI-sensitive, non-
photobleachable porphysome photothermal agent. Angew
Chem Int Ed Engl 2014;53:6956–6959.
[73] Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI
contrast agents. Adv Mater 2009;21:2133–2148.
[74] Lee N, Kim H, Choi SH, et al. Magnetosome-like
ferrimagnetic iron oxide nanocubes for highly sensitive MRI
of single cells and transplanted pancreatic islets. Proc Natl
Acad Sci USA 2011;108:2662–2667.
[75] Smith CE, Ernenwein D, Shkumatov A, et al. Hydrophilic
packaging of iron oxide nanoclusters for highly sensitive
imaging. Biomaterials 2015;69:184–190.
[76] Yu J, Chu X, Hou Y. Stimuli-responsive cancer therapy based
on nanoparticles. Chem Commun (Camb) 2014;50:11614–
11630.
[77] Mura S, Nicolas J, Couvreur P. Stimuli-responsive
nanocarriers for drug delivery. Nat Mater 2013;12:991–1003.
[78] Deelman LE, Decleves AE, Rychak JJ, et al. Targeted renal
therapies through microbubbles and ultrasound. Adv Drug
Deliv Rev 2010;62:1369–1377.
[79] Weiyang L, Xin C, Chulhong K, et al. Gold nanocages covered
with thermally-responsive polymers for controlled release
by high-intensity focused ultrasound. Nanoscale
2011;3:1724–1730.
[80] Moon GD, Choi SW, Cai X, et al. A new theranostic system
based on gold nanocages and phase-change materials with
unique features for photoacoustic imaging and controlled
release. J Am Chem Soc 2011;133:4762–4765.
[81] Geers B, Dewitte H, De Smedt SC, et al. Crucial factors and
emerging concepts in ultrasound-triggered drug delivery.
J Control Release 2012;164:248–255.
[82] Liang X, Gao J, Jiang L, et al. Nanohybrid liposomal
cerasomes with good physiological stability and rapid
temperature responsiveness for high intensity focused
ultrasound triggered local chemotherapy of cancer. ACS
Nano 2015;9:1280–1293.
[83] Pitt WG, Husseini GA, Staples BJ. Ultrasonic drug delivery – a
general review. Expert Opin Drug Deliv 2004;1:37–56.
[84] Schroeder A, Honen R, Turjeman K, et al. Ultrasound
triggered release of cisplatin from liposomes in murine
tumors. J Control Release 2009;137:63–68.
[85] Kooiman K, Vos HJ, Versluis M, et al. Acoustic behavior of
microbubbles and implications for drug delivery. Geophys
Res Lett 2001;28:4283–4286.
[86] De Cock I, Lajoinie G, Versluis M, et al. I. Sonoprinting and
the importance of microbubble loading for the ultrasound
mediated cellular delivery of nanoparticles. Biomaterials
2016;83:294–307.
[87] Klibanov AL. Microbubble contrast agents: targeted
ultrasound imaging and ultrasound-assisted drug-delivery
applications. Invest Radiol 2006;41:354–362.
[88] Eunah K, Hyun Su M, Jaeyoung L, et al. Nanobubbles from
gas-generating polymeric nanoparticles: ultrasound imaging
of living subjects. Angew Chem Int Ed Engl 2010;49:524–528.
[89] Lee JW, Jung MC, Park HD, et al. Synthesis and
characterization of thermosensitive chitosan copolymer as a
novel biomaterial. J Biomater Sci Polymer, Edn 2004;15:214–
303.
[90] Lee J, Min HS, You DG, et al. Theranostic gas-generating
nanoparticles for targeted ultrasound imaging and
treatment of neuroblastoma. J Control Release 2016;223:197–
206.
[91] Huynh E, Leung BY, Helfield BL, et al. In situ conversion of
porphyrin microbubbles to nanoparticles for multimodality
imaging. Nat Nanotechnol 2015;10:325–332.
[92] Li WP, Su CH, Chang YC, et al. Ultrasound-induced reactive
oxygen species mediated therapy and imaging using a
Fenton reaction activable polymersome. ACS Nano
2016;10:2017–2027.
595a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 5 8 5 – 5 9 5
